v3.26.1
Shareholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2025
Shareholders’ Equity [Abstract]  
Schedule of Share Options Granted

The fair value of the successor’s share options granted during the period commencing July 24, 2024 through December 31, 2024 was estimated using the black Scholes model using the following range assumptions:

 

Description  December 31,
2024		 
     
Risk-free interest rate   4.51%
Expected volatility   105.6%
Dividend yield   0 
Expected term   10 
Exercise price (USD)   0.3 
Schedule of Share-Based Expenses Recognized

Share-based expenses recognized in the financial statements:

 

   Successor   Predecessor 
   For the
year ended
December 31		   For the period
commencing
July 24
through
December 31		   For the period
commencing
January 1
through
July 23		 
   2025   2024   2024 
             
Research and development expenses   103    709    710 
General and administrative expenses   521    580    
-
 
                
Net loss and comprehensive loss   624    1,289    710 
Schedule of Share-Based Payment Arrangement Option
   Predecessor 
   Number of
options		   Weighted
average
exercise
price		   Weighted
average
remaining
contractual
terms
(in years)		   Aggregate
intrinsic
value		 
                 
Outstanding at December 31, 2023   5,657    100    9.88    
     -
 
Grants   8,600    100    10    
-
 
Outstanding at July 23, 2024   14,257    100    9.61    
-
 
                     
Vested and expected to vest at July 23, 2024   7,129    100    9.61    
-
 
Exercisable at July 23, 2024   7,129    100    9.61    
-
 
   Successor 
   Number of
options		   Weighted
average
exercise
price		   Weighted
average
remaining
contractual
terms
(in years)		   Aggregate
intrinsic
value		 
                 
Outstanding at July 24, 2024   7,020,000    0.18    6.1    
    -
 
Grants   740,000    0.3    10    
-
 
Exercised   (2,800,000)               
                     
Outstanding at December 31, 2024   4,960,000    0.3    6.1    
-
 
                     
Vested and expected to vest at December 31, 2024   4,960,000    0.3    6.1    
-
 
                     
Exercisable at December 31, 2024   3,790,000    0.38    5.1    
-
 

 

   Successor 
   Number of
options		   Weighted
average
exercise
price		   Weighted
average
remaining
contractual
terms
(in years)		   Aggregate
intrinsic
value		 
                 
Outstanding at January 1, 2025   4,960,000    0.3    6.1    
    -
 
Forfeited   (690,000)   
-
    -    - 
                     
Outstanding at December 31, 2025   4,270,000    0.3    4.9    
-
 
                     
Vested and expected to vest at December 31, 2025   4,270,000    0.3    4.9    
-
 
                     
Exercisable at December 31, 2025   4,270,000    0.38    5.1    
-